After failing to reach an agreement with Genzyme Corp’s management, Sanofi-Aventis has launched a public tender for all of the outstanding shares of the US biotechnology company that values the concern at $18.5 billion. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
